Related Experiment Videos
Gangliosides for acute ischaemic stroke
1Istituto di Clinica Neurologica, Università degli Studi di Milano, IRCCS Ospedale Policlinico, Via F. Sforza 35, Milano, Italy, 20122. livia.candelise@unimi.it
The Cochrane Database of Systematic Reviews
|November 1, 2001
Summary
Exogenous gangliosides did not show significant benefits for acute ischemic stroke patients in a review of 12 trials. Caution is advised due to rare adverse events like Guillain-Barré syndrome following ganglioside therapy.
Area of Science:
- Neurology
- Pharmacology
- Clinical Trials
Background:
- Gangliosides are complex lipids with potential neuroprotective effects on the central and peripheral nervous systems.
- Investigating exogenous gangliosides for therapeutic interventions in neurological conditions is an active area of research.
Purpose of the Study:
- To systematically evaluate the efficacy and safety of exogenous gangliosides in patients experiencing acute ischemic stroke.
- To synthesize evidence from randomized controlled trials comparing gangliosides with placebo or standard care.
Main Methods:
- A comprehensive literature search was conducted using the Cochrane Stroke Group trials register and direct contact with investigators.
- Inclusion criteria focused on randomized trials in acute ischemic stroke patients, with treatment initiated within 15 days of symptom onset and available mortality data.
- Data extraction and quality assessment were performed independently by two reviewers.
Main Results:
- Twelve trials involving 2265 patients, all using monosialoganglioside GM1, were included in the analysis.
- No significant difference in mortality was observed between ganglioside treatment and control groups (OR 0.91, 95% CI 0.73 to 1.13).
- Ganglioside treatment did not demonstrate improvement in disability scores (Barthel index), and adverse events, including Guillain-Barré syndrome, were reported.
Conclusions:
- Current evidence is insufficient to support the use of exogenous gangliosides for treating acute ischemic stroke.
- The potential risk of serious adverse events, such as Guillain-Barré syndrome, necessitates caution when considering ganglioside therapy.